Artiva Biotherapeutics Launches with $78 Million Series A Financing to Advance NK Cell Therapies to Treat Cancer

SAN DIEGO–(BUSINESS WIRE)– #NKcells–Artiva Biotherapeutics, Inc., announced today the launch of the company with the close of a $78 million Series A financing to advance NK cell therapy.